Consolidation has created a widening gulf between small start-ups with innovative technology and large multi-faceted companies that control sales and distribution channels, making life difficult for mid-sized companies caught in the middle. Nowhere is this more true than in orthopedic devices. Now, some investors are finding opportunities in mid-sized companies by using them as platforms to build more substantial plays. The goal isn't market leadership, but value creation for shareholders, which can be done on a more modest scale.
by David Cassak
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
As the health care industry undergoes a digital transformation, the integration of AI into Quality and Regulatory Management Systems is proving essential. The challenges for successful AI deployment emphasize the need for robust digital infrastructure, data literacy programs and privacy measures to enhance patient safety and commercial performance.
Aurion Biotech is developing a cell therapy for corneal diseases that is cheap enough to produce and can be scaled that it should reach the masses in a way that other cell therapies cannot.
Companies are exploring new mechanisms of action beyond traditional amyloid and tau and both investors and big pharma are willing to make deals when the science is compelling, panelists at Biotech Showcase said.
